Curocell

Curocell FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Curocell (372320.KQ) as of Oct 27, 2026 is 69.56 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 77.49 % — a change of -10.24% (lower).

FCF Conversion

69.56 %

YoY

-10.24%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Curocell is 2025 69.56 % . FCF Conversion Rate (FCF/EBITDA) of Curocell was 2024 77.49 % . It decreases by -10.24% lower compared to the previous year.

The Curocell FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
38.89 KRW
Jan 1, 2022
108.68 KRW
Jan 1, 2023
158.63 KRW
Jan 1, 2024
77.49 KRW
Jan 1, 2025
69.56 KRW
The Curocell FCF Conversion history
YEARFCF ConversionYoY
69.56 %-10.24%
77.49 %-51.15%
158.63 %+45.96%
108.68 %+179.47%
38.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

FCF Conversion Rate (FCF/EBITDA) of Curocell is 69.56 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Curocell changed from 77.49 % to 69.56 %, representing a -10.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Curocell since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Curocell with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curocell

All Key Metrics — Curocell